PDI, Inc. Improves Labeling for its Line of Pre-Moistened Wipes
Professional Disposables International, Inc. (PDI®) introduces new package graphics and color scheme for its line of skin antiseptic and patient care products. The products are more easily identifiable by featuring an illustration of the prep pad, swabstick or towelette, so the healthcare professional can quickly identify the type of applicator. In addition, the improved labeling better communicates proper use, storage and disposal information.
PDI products incorporating the change are: Chlorascrub™, Alcohol Prep Pads, PVP Iodine Prep Pads and Swabsticks, Hygea® Flushable Wipes, Hygea® Sterile Saline Wipes, Hygea® Personal Cleansing Washcloths, Hygea® Hand & Face, Hygea® Barrier Wipes, Hygea® Obstetrical Towelette, Hygea® Lemon Glycerine Oral Care Swabstick, Saliswab Oral Care Swabstick, Nice ‘n Clean Baby Wipes, Nice ‘n Clean Antibacterial Wipes, BZK Antiseptic Towelette, Castile Soap Towelette, Adhesive Tape Remover, Lubricating Jelly, Nail Polish Remover Pads, See Clear® Eye Glass Cleaning Wipes.
This is a packaging change only. All PDI, Inc. brands will retain the same formulations for infection control and prevention as well as hand sanitation and surface disinfection.
Source: PDI
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
The Role of Environmental Hygiene in Preventing Antimicrobial Resistance
March 19th 2024Uncover the pivotal role of environmental hygiene in thwarting antimicrobial resistance (AMR) for infection prevention teams. Learn how rigorous cleaning protocols and advanced technologies enhance patient safety and combat AMR.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
